Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 120-123

  Dowsett, Mitch ^a,b   Smith, Ian ^a   Robertson, John ^c   Robison, Laura ^b   Pinhel, Isabel ^a,b   Johnson, Lindsay ^b   Salter, Janine ^a,b   Dunbier, Anita ^a,b   Anderson, Helen ^a,b   Ghazoui, Zara ^a,b   Skene, Tony ^d   Evans, Abigail ^e   A'Hern, Roger ^b   Iskender, Amanda ^d   Wilcox, Maggie ^f   Bliss, Judith ^b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^e POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f The National Cancer Research Institute Consumer Liaison Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; CELECOXIB; ERLOTINIB; GEFITINIB; KI 67 ANTIGEN; LAPATINIB; LETROZOLE; TAMOXIFEN; VOROZOLE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; NITRILE; PROGESTERONE RECEPTOR; QUINAZOLINE DERIVATIVE; TRIAZOLE DERIVATIVE; TUMOR MARKER;

ADJUVANT THERAPY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CLONAL VARIATION; DISEASE FREE SURVIVAL; DNA POLYMORPHISM; DRUG MECHANISM; DRUG SAFETY; EPIGENETICS; FOLLOW UP; GENE EXPRESSION; HUMAN; MEDICAL ETHICS; MUTATION RATE; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL (TOPIC); POSTMENOPAUSE; PREDICTOR VARIABLE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUMOR GROWTH; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; CLINICAL TRIAL (TOPIC); ETHICS; FEMALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PREDICTIVE VALUE; PREOPERATIVE PERIOD; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; KI-67 ANTIGEN; MOLECULAR TARGETED THERAPY; MULTICENTER STUDIES AS TOPIC; NEOADJUVANT THERAPY; NITRILES; PREDICTIVE VALUE OF TESTS; PREOPERATIVE PERIOD; QUINAZOLINES; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84855161481     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr034     Document Type: Article

References (14)

1. Harper-Wynne CL, Sacks NP, Shenton K, et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J Clin Oncol. 2002;20(4):1026-1035.
2. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005;11(2, pt 2):951s-958s.
3. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer
4. Smith IE, Walsh G, Skene A, et al. A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. J Clin Oncol. 2007;25(25):3816-3822.
5. Guix M, Granja Nde M, Meszoely I, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol. 2008;26(6):897-906.
6. Martin L-A, Davies GLS, Weigel MT, et al. Pre-surgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat. 2010;123(3):829-836.
7. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769-777.
8. Assersohn L, Salter J, Powles TJ. Studies of the potential utility of Ki67 as a predictive molecular marker of clinical response in primary breast cancer. Breast Cancer Res Treat. 2003;82(2):113-123.
9. Mackay A, Urruticoechea A, Dixon JM, et al. Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res. 2007;9(3):R37.
10. Ghazoui Z, Buffa FM, Dunbier AK, et al. Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibit treated ER-positive breast cancer. Clin Cancer Res. 2011;17(9):3005-3012.
11. Dunbier AK, Ghazoui Z, Anderson H, Smith IE, Dowsett M. Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumours identifies determinants of response. Cancer Res. 2010;70(24 suppl):80s.
12. Fisher B, Saffer E, Rudock C, Coyle J, Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res. 1989;49(8):2002-2004.
13. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol. 2002;20(3):751-757.
14. Dixon JM, Renshaw L, Young O, et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol. 2008;26(10):1671-1676.